LENSAR, Inc. (LNSR)
NASDAQ: LNSR · Real-Time Price · USD
5.34
-0.01 (-0.19%)
At close: Apr 29, 2026, 4:00 PM EDT
5.39
+0.05 (0.94%)
After-hours: Apr 29, 2026, 4:10 PM EDT

Company Description

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally.

The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.

It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room.

LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

LENSAR, Inc.
LENSAR logo
Country United States
Founded 2004
Industry Medical Devices
Sector Healthcare
Employees 150
CEO Nicholas Curtis

Contact Details

Address:
2800 Discovery Drive
Orlando, Florida 32826
United States
Phone 888 536 7271
Website lensar.com

Stock Details

Ticker Symbol LNSR
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001320350
CUSIP Number 52634L108
ISIN Number US52634L1089
Employer ID 32-0125724
SIC Code 3841

Key Executives

Name Position
Nicholas T. Curtis President, Chief Executive Officer and Director
Thomas R. Staab II, CPA Chief Financial Officer and Secretary
Alan B. Connaughton Chief Operating Officer
Kendra W. Wong Principal Accounting Officer

Latest SEC Filings

Date Type Title
Apr 15, 2026 8-K Current Report
Mar 31, 2026 10-K Annual Report
Mar 31, 2026 8-K Current Report
Mar 17, 2026 8-K Current Report
Mar 13, 2026 8-K/A [Amend] Current report
Mar 12, 2026 8-K Current Report
Feb 25, 2026 8-K Current Report
Dec 19, 2025 8-K Current Report
Nov 13, 2025 SCHEDULE 13G Filing
Nov 6, 2025 10-Q Quarterly Report